Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: Comparison with the era before 7-valent conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 32, Issue 2, 2013, Pages

  Sharma, Dolly ^a,b   Baughman, Wendy ^c   Holst, Amy ^c   Thomas, Stephanie ^c   Jackson, Delois ^d   Da Gloria Carvalho, Maria ^d   Beall, Bernard ^d   Satola, Sarah ^a,c   Jerris, Robert ^b   Jain, Shabnam ^a,b   Farley, Monica M ^a,c   Nuorti, J Pekka ^d,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

antimicrobial resistance; carriage; conjugate vaccines; invasive pneumococcal disease; Streptococcus pneumoniae

Indexed keywords

CEFOTAXIME; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CHILDHOOD DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HEALTH SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NASOPHARYNX; OUTPATIENT CARE; PNEUMOCOCCAL INFECTION; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE;

CARRIER STATE; CHI-SQUARE DISTRIBUTION; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; GEORGIA; HUMANS; INFANT; MALE; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 84873057707     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182788fdd     Document Type: Article

References (56)

1. O'Brien KL, Wolfson LJ, Watt J P, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
2. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol. 1995;33:2759-2762.
3. Park IH, Pritchard DG, Cartee R, et al. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225-1233.
4. Bogaert D, De Groot R, Hermans P W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144-154.
5. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb and Mortal Wkly Rep. 2000;49:1-38.
6. Albrich WC, Baughman W, Schmotzer B, et al. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1569-1576.
7. Carvalho MDAG, Pimenta FC, Gertz RE JR, et al.; Active Bacterial Core Surveillance Team. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol. 2009;47:554-559.
8. Black S, France EK, Isaacman D, et al. Surveillance for invasive pneu-mococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:771-777.
9. Kaplan SL, Mason EO JR, Wald ER, et al. Decrease of invasive pneumococ-cal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3, pt 1):443-449.
10. Whitney CG, Farley MM, Hadler J, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
11. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
12. Clarke SC, Jefferies JM, Smith AJ, et al. Pneumococci causing invasive disease in children prior to the introduction of pneumococcal conjugate vaccine in Scotland. J Med Microbiol. 2006;55(pt 8):1079-1084.
13. O'Brien KL, Nohynek H; World Health Organization Pneumococcal Vaccine Trials Carriage Working Group. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J. 2003;22:e1-e11.
14. Cheung YB, Zaman SM, Nsekpong ED, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J. 2009;28:990-995.
15. Dagan R, Givon-Lavi N, Zamir O, et al. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J. 2003;22:532-540.
16. Black SB, Shinefeld HR, Hansen J, et al. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:1105-1107.
17. Finkelstein JA, Huang SS, Daniel J, et al. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics. 2003;112: 862-869.
18. Malfroot A, Verhaegen J, Dubru JM, et al. A cross-sectional survey of the prevalence of Streptococcus pneumoniae nasopharyngeal carriage in Belgian infants attending day care centres. Clin Microbiol Infect. 2004;10: 797-803.
19. Singleton RJ, Hennessy T W, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-1792.
20. Centers for Disease Control and Prevention. Licensure of a 13-valent pneu-mococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:258-261.
21. O'Brien KL, Bronsdon MA, Dagan R, et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during feld studies. J Clin Micro-biol. 2001;39:1021-1024.
22. Schuchat A, Hilger T, Zell E, et al.; Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Active bacterial core surveillance of the emerging infections program network. Emerging Infect Dis. 2001;7:92-99.
23. Da Gloria Carvalho M, Pimenta FC, Jackson D, et al. Revisiting pneumococ-cal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. J Clin Microbiol. 2010;48:1611-1618.
24. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eigteenth Informational Supplement. CLSI Document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
25. Lund E. Laboratory diagnosis of Pneumococcus infections. Bull World Health Organ. 1960;23:5-13.
26. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identifcation of clones associated with serious invasive disease. Microbiology (Reading, Engl). 1998;144(pt 11):3049-3060.
27. Gertz RE JR, McEllistrem MC, Boxrud DJ, et al. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol. 2003;41:4194-4216.
28. Park IH, Park S, Hollingshead SK, et al. Genetic basis for the new pneumo-coccal serotype, 6C. Infect Immun. 2007;75:4482-4489.
29. Moore MR, Gertz RE JR, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016-1027.
30. Beall B W, Gertz RE, Hulkower RL, et al. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203:1360-1368.
31. Hanage W P, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis. 2007;195: 347-352.
32. Pai R, Moore MR, Pilishvili T, et al.; Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988-1995.
33. Choi EH, Kim SH, Eun B W, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerging Infect Dis. 2008;14:275-281.
34. Kyaw MH, Lynfeld R, Schaffner W, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-1463.
35. Croney CM, Coats MT, Nahm MH, Briles DE, Crain MJ. PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin Vaccine Immunol. 2012;19:891-896.
36. Casado-Flores J, Rodrigo C, Arístegui J, et al. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2008;27:1020-1022.
37. Huang SS, Platt R, Rifas-Shiman SL, et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics. 2005;116:e408-e413.
38. Messina AF, Katz-Gaynor K, Barton T, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, Children from 1999 through 2005. Pediatr Infect Dis J. 2007;26:461-467.
39. Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in sero-types and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J. 2004;23:1015-1022.
40. Cohen R, Levy C, De La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006;25:1001-1007.
41. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(suppl 3):16-20.
42. Brueggemann AB, Pai R, Crook DW, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3:e168.
43. Dagan R, Givon-Lavi N, Leibovitz E, et al. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis. 2009;199:776-785.
44. Robinson KA, Baughman W, Rothrock G, et al Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729-1735.
45. Sleeman KL, Griffths D, Shackley F, et al. Capsular serotype-specifc attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis. 2006;194:682-688.
46. Park SY, Moore MR, Bruden DL, et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J. 2008;27:335-340.
47. Porat N, Arguedas A, Spratt BG, et al. Emergence of penicillin-nonsus- ceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J Infect Dis. 2004;190: 2154-2161.
48. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneu-moniae-Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep. 2007;56:1077-1080.
49. Picazo JJ. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines. Clin Microbiol Infect. 2009;15(suppl 3):4-6.
50. Pichichero ME, Casey Jr. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298:1772-1778.
51. Dunais B, Bruno P, Carsenti-Dellamonica H, et al. Trends in nasopharyngeal carriage of Streptococcus pneumoniae among children attending daycare centers in southeastern France from 1999 to 2006. Pediatr Infect Dis J. 2008;27:1033-1035.
52. Van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302:159-167.
53. Varon E, Levy C, De La Rocque F, et al. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus infuenzae, and Branhamella catarrhalis in children with respiratory tract infections. Clin Infect Dis. 2000;31:477-481.
54. Brugger SD, Hathaway LJ, Mühlemann K. Detection of Streptococcus pneumoniae strain cocolonization in the nasopharynx. J Clin Microbiol. 2009;47:1750-1756.
55. Huebner RE, Dagan R, Porath N, et al. Lack of utility of serotyping multiple colonies for detection of simultaneous nasopharyngeal carriage of different pneumococcal serotypes. Pediatr Infect Dis J. 2000;19:1017-1020.
56. Sá-Leão R, Tomasz A, Santos Sanches I, et al. Pilot study of the genetic diversity of the pneumococcal nasopharyngeal fora among children attending day care centers. J Clin Microbiol. 2002;40:3577-3585.